- Home
- VYGR vs CUB Comparison
VYGR vs CUB Comparison
Compare VYGR & CUB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- CUB
- Stock Information
- Founded
- VYGR 2013
- CUB 2024
- Country
- VYGR United States
- CUB United States
- Employees
- VYGR N/A
- CUB N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- CUB
- Sector
- VYGR Health Care
- CUB
- Exchange
- VYGR Nasdaq
- CUB NYSE
- Market Cap
- VYGR 342.5M
- CUB 307.3M
- IPO Year
- VYGR 2015
- CUB 2024
- Fundamental
- Price
- VYGR $5.75
- CUB $10.09
- Analyst Decision
- VYGR Strong Buy
- CUB
- Analyst Count
- VYGR 9
- CUB 0
- Target Price
- VYGR $16.44
- CUB N/A
- AVG Volume (30 Days)
- VYGR 485.6K
- CUB 60.5K
- Earning Date
- VYGR 11-12-2024
- CUB 01-01-0001
- Dividend Yield
- VYGR N/A
- CUB N/A
- EPS Growth
- VYGR N/A
- CUB N/A
- EPS
- VYGR 0.47
- CUB N/A
- Revenue
- VYGR $163,784,000.00
- CUB N/A
- Revenue This Year
- VYGR N/A
- CUB N/A
- Revenue Next Year
- VYGR N/A
- CUB N/A
- P/E Ratio
- VYGR $12.33
- CUB N/A
- Revenue Growth
- VYGR 3.40
- CUB N/A
- 52 Week Low
- VYGR $5.19
- CUB $9.96
- 52 Week High
- VYGR $11.72
- CUB $10.55
- Technical
- Relative Strength Index (RSI)
- VYGR 41.30
- CUB N/A
- Support Level
- VYGR $6.08
- CUB N/A
- Resistance Level
- VYGR $6.55
- CUB N/A
- Average True Range (ATR)
- VYGR 0.35
- CUB 0.00
- MACD
- VYGR -0.05
- CUB 0.00
- Stochastic Oscillator
- VYGR 14.51
- CUB 0.00
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About CUB LIONHEART HOLDINGS
Lionheart Holdings is a blank check company.